Status:
TERMINATED
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
Lead Sponsor:
Genmab
Conditions:
Head and Neck Cancer
Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to investigate the safety of zalutumumab in combination with radiotherapy as the treatment of patients with head and neck cancer who are not eligible for platinum based ch...
Detailed Description
This is an open label, multi-center, phase I/II dose-escalation clinical trial investigating the safety of zalutumumab in combination with radiotherapy. The safety of zalutumumab doses in combination ...
Eligibility Criteria
Inclusion
- Patients with histologically or cytologically confirmed diagnosis of locally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx stage III, IVa or IVb
- Measurable disease defined as one or more target lesions according to RECIST based onCT scan or MRI and clinical evaluation
- Eligible for intended curative radiotherapy
- Patients considered ineligible for platinum based chemotherapy based on investigator's judgment
- Age \> 18 years
- Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out
Exclusion
- Prior radiotherapy to the head and neck area
- Prior chemotherapy administered for cancer in the head and neck area
- Prior targeted therapy (e.g. EGFR antibodies or EGFR inhibitors)
- Received the following treatments within 4 weeks prior to Visit 2:
- Retinoic acid
- Other immunosuppressive drugs (e.g. drugs interfering with the functions of T cells, IL-2 or equivalent)
- Any non-marketed drug substance
- Past or current malignancy other than SCCHN, except for:
- Cervical carcinoma Stage 1B or less
- Non-invasive basal cell skin carcinoma
- Squamous cell skin carcinoma
- Stage 1 or 2 treated prostate cancer with PSA in the normal range for \>2 years post treatment
- Malignant melanoma with a complete response duration of \> 10 years
- Other cancer diagnoses with a complete response duration of \> 5 years
- Metastatic SCCHN disease
- Chronic or current infectious disease such as, but not limited to, chronic renal infection and tuberculosis
- Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months before Visit 1, congestive heart failure, and arrhythmia requiring anti-arrhythmic therapy, with the exception of extra systoles or minor conduction abnormalities
- Significant concurrent, uncontrolled medical condition including, but not limited to,hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease considered to preclude trial treatment and/or compliance according to the Investigator's opinion, or any other condition preventing therapy according to the Investigator's opinion
- Known HIV positive
- Known active hepatitis B and/or hepatitis C
- Screening laboratory values:
- Neutrophils \< 1.5 x 109/L
- Platelets \< 100 x109/L
- Hemoglobin \< 6 mmol/L
- Current participation in any other interventional clinical study
- Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency, or psychological disorder)
- Known or suspected hypersensitivity to components of the investigational medicinal Product
- Breast feeding women or women with a positive pregnancy test at screening blood Sample
- Males not willing to use adequate contraception during study and for 12 months after last dose of zalutumumab or women of childbearing potential not willing to use adequate contraception as hormonal birth control or intrauterine device during study and for 12 months after last dose of zalutumumab
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00707655
Start Date
September 1 2008
End Date
October 1 2010
Last Update
August 3 2023
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
St-Luc University Hospital
Brussels, Belgium
2
Centre Georges-Francois Leclerc Hospital
Dijon, France
3
Medical Oncology, Outpatient Clinic
Nantes, France
4
Institut Claudius Regaud Toulouse
Toulouse, France